RxDoctor Payments Data

Nitin Patel, MD

Cardiology · Prescott Valley, AZNPI 1780620484

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Boston Scientific at 40.0% of the total. 2025 is the largest year on record at $513, 4.7 times the $108 reported in 2019.

$1,886in general payments, 2019–2025

Across 100 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$755
  • Abbott$618
  • Medicomp Inc$127
  • Amgen$101
  • Impulse Dynamics (USA) Inc.$91
  • Johnson & Johnson$60
  • plus $134 from 3 others

What the payments were for

  • Food & beverage$1,886100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific44$755
Abbott29$618
Medicomp Inc6$127
Amgen5$101
Impulse Dynamics (USA) Inc.5$91
Johnson & Johnson4$60
Cvrx, Inc.3$60
Novo Nordisk2$37
Pfizer2$37

How this compares

Too few cardiology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$709,037
Medicare patients
815
Services billed
5,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban213$269,214
XareltoRivaroxaban38$42,545
BrilintaTicagrelor11$11,749
Repatha SureclickEvolocumab12$8,883
Verapamil ErVerapamil Hcl93$2,284
Verapamil SrVerapamil Hcl19$2,177
Carvedilol263$2,078
Losartan Potassium214$1,717
Atorvastatin Calcium169$1,641
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide90$1,226
Lisinopril231$1,183
Metoprolol Succinate127$1,139
Spironolactone147$983
Flecainide Acetate17$821
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid94$800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$269,214213 claims
Johnson & JohnsonXarelto$60$42,54538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other cardiology in Prescott Valley

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →